NGS is suitable for almost all of mutations appearing in the NSCLC, such as EGFR, RET, MET, ALK, HER2, BRAF, ROS1, KRAS, and NTRK, also including some new biomarkers such as PIK3CA (103). The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.